JG
ECYT

Joel Greenblatt’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Joel Greenblatt’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-17,450
Closed -$106K – 1101
2014
Q3 		$106K Buy
+17,450
New +$119K ﹤0.01% 967

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Joel Greenblatt's ECYT Position: Q4 2014 in Review

Joel Greenblatt sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2014, closing a stake of 17,450 shares — an estimated $106K sold.

Joel Greenblatt first reported a position in ECYT in Q3 2014 and held it in 1 quarter. The position peaked at $106K in Q3 2014. 100 funds tracked by Wall St. Rank hold ECYT as of Q4 2014.

  • Joel Greenblatt reported no remaining Endocyte, Inc. Common Stock position as of Q4 2014 after selling out during the quarter.
  • Joel Greenblatt sold 17,450 Endocyte, Inc. Common Stock shares in Q4 2014, an estimated $106K.
  • Joel Greenblatt first reported a position in Endocyte, Inc. Common Stock in Q3 2014 and held it in 1 quarter.
  • Joel Greenblatt's Endocyte, Inc. Common Stock position peaked at $106K in Q3 2014.
  • 100 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2014.

Based on Gotham Asset Management's 13F filing for Q4 2014, filed 17 Feb 2015.